{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:10:28Z","timestamp":1783944628017,"version":"3.55.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the experiences and perspectives of community pharmacists in Ireland on Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An online questionnaire of closed- and open-ended questions was distributed to community pharmacists in the Republic of Ireland in July 2025. Closed-ended questions were analyzed quantitatively using descriptive statistics, and conventional content analysis was utilized for open-ended responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>Two hundred questionnaires were available for analysis. Respondents dispensed GLP-1 RAs for obesity (n\u2009=\u200931, 16.1%), and for both obesity and diabetes management (n\u2009=\u2009160, 82.9%). Respondents frequently provided counselling on the practical aspects of GLP-1 RA use including storage (n\u2009=\u2009162, 83.94%), administration (n\u2009=\u2009143, 74.09%), side effects (n\u2009=\u2009128, 66.32%), and sharps disposal (n\u2009=\u200999, 51.3%). However, topics such as nutrition and contraception were discussed less frequently, with 45.6% (n\u2009=\u200988) never providing contraception advice to female patients. Time constraints were the main barriers reported to counselling. Several challenges and concerns were highlighted by pharmacists including the impact of medication shortages on practice, increased pressure on pharmacy workflows, safety and prescribing oversight, particularly for online prescribing, alongside a need for additional education and training.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Community pharmacists in Ireland play a key role in dispensing GLP-1 RAs and providing patient support. They report gaps in counselling, training, professional guidance, and structural support, alongside safety concerns of online prescribing. Updated professional guidance, pharmacy-based practice models, and national policies will allow community pharmacists to better support the delivery of obesity care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijpp\/riag090","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:20:55Z","timestamp":1783941655000},"source":"Crossref","is-referenced-by-count":0,"title":["Community pharmacists\u2019 experiences and perspectives on GLP-1 receptor agonists for obesity management: a cross-sectional study in Ireland"],"prefix":"10.1093","author":[{"given":"Jenny","family":"Demmel","sequence":"first","affiliation":[{"name":"School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences , Dublin D02 VN51 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3477-6992","authenticated-orcid":false,"given":"Ciara","family":"Farrell","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences , Dublin D02 VN51 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-6003","authenticated-orcid":false,"given":"Claire M","family":"Timon","sequence":"additional","affiliation":[{"name":"School of Population Health, Royal College of Surgeons in Ireland , Dublin D02 X0N1 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Cleary","sequence":"additional","affiliation":[{"name":"School of Population Health, Royal College of Surgeons in Ireland , Dublin D02 X0N1 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah L","family":"Christie","sequence":"additional","affiliation":[{"name":"School of Population Health, Royal College of Surgeons in Ireland , Dublin D02 X0N1 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noreen","family":"O\u2019Leary","sequence":"additional","affiliation":[{"name":"School of Population Health, Royal College of Surgeons in Ireland , Dublin D02 X0N1 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine V","family":"George","sequence":"additional","affiliation":[{"name":"School of Population Health, Royal College of Surgeons in Ireland , Dublin D02 X0N1 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Dunne","sequence":"additional","affiliation":[{"name":"School of Population Health, Royal College of Surgeons in Ireland , Dublin D02 X0N1 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Mitchell","sequence":"additional","affiliation":[{"name":"School of Population Health, Royal College of Surgeons in Ireland , Dublin D02 X0N1 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-5445","authenticated-orcid":false,"given":"Carel W","family":"le Roux","sequence":"additional","affiliation":[{"name":"Diabetes Complications Research Centre, Conway Institute, University College Dublin , Dublin D04 V1W8, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathal","family":"O\u2019Hara","sequence":"additional","affiliation":[{"name":"School of Population Health, Royal College of Surgeons in Ireland , Dublin D02 X0N1 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Flood","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences , Dublin D02 VN51 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8438-1506","authenticated-orcid":false,"given":"Angela C","family":"Flynn","sequence":"additional","affiliation":[{"name":"School of Population Health, Royal College of Surgeons in Ireland , Dublin D02 X0N1 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"2026071307204881200_ref1","volume-title":"Obesity and Overweight [Fact Sheet]","author":"World Health Organisation (WHO)","year":"2025"},{"key":"2026071307204881200_ref2","volume-title":"Healthy Ireland Survey \u2013 Summary Report 2024","author":"Government of Ireland","year":"2024"},{"key":"2026071307204881200_ref3","first-page":"s176","article-title":"Obesity: definition, comorbidities, causes, and burden","volume":"22","author":"Apovian","year":"2016","journal-title":"Am J Manag Care"},{"key":"2026071307204881200_ref4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s13679-023-00495-3","article-title":"Obesity stigma: causes, consequences, and potential solutions","volume":"12","author":"Westbury","year":"2023","journal-title":"Curr Obes Rep"},{"key":"2026071307204881200_ref5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2026071307204881200_ref6","volume-title":"Model of Care for the Management of Overweight and Obesity","author":"Health Service Executive","year":"2020"},{"key":"2026071307204881200_ref7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"2026071307204881200_ref8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026071307204881200_ref9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly Semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026071307204881200_ref10","volume-title":"Pharmacotherapy","author":"Specialist College of Healthcare Management"},{"key":"2026071307204881200_ref11","doi-asserted-by":"publisher","first-page":"e002519","DOI":"10.1136\/bmjph-2024-002519","article-title":"What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional survey study in the UK","volume":"3","author":"Auerbach","year":"2025","journal-title":"BMJ Public Health"},{"key":"2026071307204881200_ref12","volume-title":"EU Actions to Tackle Shortages of GLP-1 Receptor Agonists","author":"European Medicines Agency","year":"2024"},{"key":"2026071307204881200_ref13","doi-asserted-by":"publisher","DOI":"10.17639\/293T-HQ17","volume-title":"Non-genuine Participation in Online Research: Guidance on Handling Potential Non-genuine Participants in Online Research","author":"French","year":"2025"},{"key":"2026071307204881200_ref14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1365-2648.2007.04569.x","article-title":"The qualitative content analysis process","volume":"62","author":"Elo","year":"2008","journal-title":"J Adv Nurs"},{"key":"2026071307204881200_ref15","volume-title":"Pharmacy Workforce Survey Analysis Report 2024","author":"Pharmaceutical Society of Ireland","year":"2024"},{"key":"2026071307204881200_ref16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026071307204881200_ref17","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.2196\/jmir.6.3.e34","article-title":"Improving the quality of web surveys: the checklist for reporting results of internet E-surveys (CHERRIES)","volume":"6","author":"Eysenbach","year":"2004","journal-title":"J Med Internet Res"},{"key":"2026071307204881200_ref18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11096-015-0102-7","article-title":"Promoting weight management services in community pharmacy: perspectives of the pharmacy team in Scotland","volume":"37","author":"Weidmann","year":"2015","journal-title":"Int J Clin Pharm"},{"key":"2026071307204881200_ref19","doi-asserted-by":"publisher","first-page":"587750","DOI":"10.2147\/DMSO.S587750","article-title":"Community pharmacists' knowledge and Counseling competence on GLP-1 receptor agonists in obesity and type 2 diabetes Care in T\u00fcrkiye: a cross-sectional study","volume":"19","author":"Bayram-Ozgur","year":"2026","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2026071307204881200_ref20","doi-asserted-by":"publisher","first-page":"e0144074","DOI":"10.1371\/journal.pone.0144074","article-title":"A qualitative study of prescription contraception use: the perspectives of users, general practitioners and pharmacists","volume":"10","author":"Sweeney","year":"2015","journal-title":"PLoS One"},{"key":"2026071307204881200_ref21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/pharmacy7030082","article-title":"Experiences of the pharmacy-led weight management service: views of service providers in England","volume":"7","author":"Peletidi","year":"2019","journal-title":"Pharmacy (Basel)"},{"key":"2026071307204881200_ref22","doi-asserted-by":"publisher","first-page":"r252","DOI":"10.1136\/bmj.r252","article-title":"Weight loss drugs: pharmacies are told to make stricter checks before prescribing","volume":"388","author":"Iacobucci","year":"2025","journal-title":"BMJ."},{"key":"2026071307204881200_ref23","volume-title":"Medicines Shortages Survey 2025","author":"Irish Pharmacy Union","year":"2025"},{"key":"2026071307204881200_ref24","volume-title":"Availability of Semaglutide (Ozempic\u00ae): Important Information for Healthcare Professionals and Patients [Internet]","author":"Health Products Regulatory Authority"},{"key":"2026071307204881200_ref25","volume-title":"Expert Taskforce to Support the Expansion of the Role of Pharmacists in Ireland","author":"Department of Health"},{"key":"2026071307204881200_ref26","volume-title":"Joint Guidance on Safe Prescribing and Dispensing of Controlled Drugs","author":"Pharmaceutical Society of Ireland","year":"2025"},{"key":"2026071307204881200_ref27","volume-title":"Guidance for Prescribers and Pharmacists on Legislation Changes to Facilitate the Safe Supply of Medicines during the COVID-19 Pandemic","author":"Pharmaceutical Society of Ireland; Health Service Executive; Irish Medical Council","year":"2020"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijpp\/advance-article-pdf\/doi\/10.1093\/ijpp\/riag090\/68763748\/riag090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijpp\/advance-article-pdf\/doi\/10.1093\/ijpp\/riag090\/68763748\/riag090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:20:58Z","timestamp":1783941658000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/advance-article\/doi\/10.1093\/ijpp\/riag090\/8733200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riag090","relation":{},"ISSN":["2042-7174"],"issn-type":[{"value":"2042-7174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"article-number":"riag090"}}